Hybrigenics Acquires Dualsystems Biotech's Yeast Two-Hybrid Business | GenomeWeb

NEW YORK (GenomeWeb News) – Hybrigenics has acquired the yeast two-hybrid assets of Swiss biotech firm Dualsystems Biotech.

The acquisition provides Hybrigenic Services, a subsidiary of Paris-based biopharma firm Hybrigenics that specializes in protein-protein interaction work, with exclusive ownership of patented yeast two-hybrid screening technology for membrane proteins. The deal will expand the company's commercial reach in German-speaking territories, Eastern Europe, and China, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.